Principal Investigator: Professor John Parrington
Institution: University of OxfordTags: 51249, biomarker, cancer, diagnosis, endolysosomal cation channels, prognosis, TPC2
Cancer is a major public health problem and one of the leading causes of death worldwide. Cancer biomarkers have emerged as clinical tools that can enhance the efficiency of detection and guide the treatment of cancer patients by providing personalised therapy and information about expected cancer outcomes. Recently, there is increasing evidence that links endolysosomal cation channels and cancer, particularly two-pore channel 2 (TPC2), revealing the potential applications of TPC2 as a biomarker in the definition of tumour types, susceptibility, prognosis, response and cancer outcomes. The mechanisms that underpin the role of TPC2 in various fundamental processes of oncogenesis, in different types of cancer and at different stages of tumour development are not fully understood. We aim to investigate the association between genetic mutations in endolysosomal cation channel genes and cancer. Furthermore, we will examine the role of the identified genetic mutations in cancer. The findings of this study might have significant implications for future practice by improving diagnosis, prognosis and treatment in cancer patients, as well as providing insights to better understand the pathogenesis of cancer.